Mario Gaudino MD, PhD , Gregg W. Stone MD , Rachel S. Heise MS , Tulio Caldonazo MD , Jessica Kim MS , Lamia Harik MD , Sigrid Sandner MD , Giuseppe Biondi-Zoccai MD, PhD , Ruth Masterson-Creber PhD, MSc, RN , John H. Alexander MD, MHS , Deepak L. Bhatt MD, MPH, MBA , John Puskas MD , P.J. Devereaux MD, PhD , John Spertus MD, MPH , Bjorn Redfors MD, PhD
{"title":"Association Between Myocardial Infarction and Quality of Life in the ISCHEMIA Trial","authors":"Mario Gaudino MD, PhD , Gregg W. Stone MD , Rachel S. Heise MS , Tulio Caldonazo MD , Jessica Kim MS , Lamia Harik MD , Sigrid Sandner MD , Giuseppe Biondi-Zoccai MD, PhD , Ruth Masterson-Creber PhD, MSc, RN , John H. Alexander MD, MHS , Deepak L. Bhatt MD, MPH, MBA , John Puskas MD , P.J. Devereaux MD, PhD , John Spertus MD, MPH , Bjorn Redfors MD, PhD","doi":"10.1016/j.jcin.2025.02.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The association between myocardial infarction (MI) subtypes (procedural MI [PMI] and spontaneous MI [SMI]) and subsequent quality of life (QoL) is incompletely understood.</div></div><div><h3>Objectives</h3><div>The authors analyzed the association between PMI and SMI and generic and disease-specific QoL in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial.</div></div><div><h3>Methods</h3><div>QoL was assessed before randomization and at 1.5, 3, and 6 months, and every 6 months thereafter. European Quality of Life-5 dimensions visual analog scale (EQ-5D VAS) (generic) and Seattle Angina Questionnaire (SAQ-7) summary score (disease-specific) were used. The primary analysis was a linear, repeated-measures, multivariable-adjusted, mixed-effects model, with a random intercept for patient. QoL assessments occurring <3 months after MI were defined as early QoL and those occurring >3 months after MI were defined as late QoL.</div></div><div><h3>Results</h3><div>A total of 4,375 randomized patients were included in the primary analysis population. The median duration of follow-up was 36.2 months (Q1-Q3: 23.8-49.5 months). In the primary analysis population, a total of 84 PMIs and 352 SMIs occurred. SMI was associated with significant decreases in both early (adjusted difference −5.7; 95% CI: −7.3 to −4.1 points) and late EQ-5D VAS (−3.1 points; 95% CI: −4.3 to −1.9 points) and in early (−7.7 points; 95% CI: −9.4 to −6.1 points) and late SAQ-7 (−1.9 points; 95% CI: −3.2 to −0.7 points). PMI was not associated with early (adjusted difference −0.8 points; 95% CI: −3.3 to 1.8 points) or late (−0.7 points; 95% CI: −2.7 to 1.2 points) changes in EQ-5D VAS, and was associated with a reduction in early (−3.0 points; 95% CI: −5.7 to −0.4) but not late SAQ-7 (−0.2 points; 95% CI −2.2 to 1.8 points).</div></div><div><h3>Conclusions</h3><div>In ISCHEMIA, SMI was associated with reductions in both early and late generic and disease-specific QoL, whereas PMI was only associated with a transient reduction in disease-specific QoL.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 10","pages":"Pages 1263-1272"},"PeriodicalIF":11.7000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Cardiovascular interventions","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936879825008052","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The association between myocardial infarction (MI) subtypes (procedural MI [PMI] and spontaneous MI [SMI]) and subsequent quality of life (QoL) is incompletely understood.
Objectives
The authors analyzed the association between PMI and SMI and generic and disease-specific QoL in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial.
Methods
QoL was assessed before randomization and at 1.5, 3, and 6 months, and every 6 months thereafter. European Quality of Life-5 dimensions visual analog scale (EQ-5D VAS) (generic) and Seattle Angina Questionnaire (SAQ-7) summary score (disease-specific) were used. The primary analysis was a linear, repeated-measures, multivariable-adjusted, mixed-effects model, with a random intercept for patient. QoL assessments occurring <3 months after MI were defined as early QoL and those occurring >3 months after MI were defined as late QoL.
Results
A total of 4,375 randomized patients were included in the primary analysis population. The median duration of follow-up was 36.2 months (Q1-Q3: 23.8-49.5 months). In the primary analysis population, a total of 84 PMIs and 352 SMIs occurred. SMI was associated with significant decreases in both early (adjusted difference −5.7; 95% CI: −7.3 to −4.1 points) and late EQ-5D VAS (−3.1 points; 95% CI: −4.3 to −1.9 points) and in early (−7.7 points; 95% CI: −9.4 to −6.1 points) and late SAQ-7 (−1.9 points; 95% CI: −3.2 to −0.7 points). PMI was not associated with early (adjusted difference −0.8 points; 95% CI: −3.3 to 1.8 points) or late (−0.7 points; 95% CI: −2.7 to 1.2 points) changes in EQ-5D VAS, and was associated with a reduction in early (−3.0 points; 95% CI: −5.7 to −0.4) but not late SAQ-7 (−0.2 points; 95% CI −2.2 to 1.8 points).
Conclusions
In ISCHEMIA, SMI was associated with reductions in both early and late generic and disease-specific QoL, whereas PMI was only associated with a transient reduction in disease-specific QoL.
期刊介绍:
JACC: Cardiovascular Interventions is a specialist journal launched by the Journal of the American College of Cardiology (JACC). It covers the entire field of interventional cardiovascular medicine, including cardiac, peripheral, and cerebrovascular interventions. The journal publishes studies that will impact the practice of interventional cardiovascular medicine, including clinical trials, experimental studies, and in-depth discussions by respected experts. To enhance visual understanding, the journal is published both in print and electronically, utilizing the latest technologies.